Hemodialysis Access Clinical Trial
— AVFOfficial title:
The Effect of Ice Application and Kaleidoscope Application on the Management of Cannulation-Related Pain in Dialysis Patients With Arteriovenous Fistula
Verified date | January 2024 |
Source | Amasya University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
It was conducted to investigate the effect of ice application to the kaleidoscope and hoku point on the management of cannulization-related pain in patients receiving hemodialysis treatment.
Status | Completed |
Enrollment | 102 |
Est. completion date | December 26, 2023 |
Est. primary completion date | June 2, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 100 Years |
Eligibility | Inclusion Criteria: Comfortable reception of trill and murmur sound from arteriovenous fistula, • over the age of 18 and no communication problems, - Having a place and time orientation, - No dizziness, Exclusion Criteria: - Hemodialysis of the patient with arteriovenous graft and/or central venous catheter - Pharmacological application was made to relieve pain 30 minutes before AVF cannulation, - The patient has a COVID - 19 infection - Having visual, auditory and intellectual disabilities, - Having a communication problem, - Not willing and willing to participate in the study, as well as wanting to withdraw from the study at any stage of the study |
Country | Name | City | State |
---|---|---|---|
Turkey | Amasya University Institute of Health Sciences | Amasya | Merkez |
Lead Sponsor | Collaborator |
---|---|
Sülayman YAMAN |
Turkey,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | visual pain scale (min-max:0-10 point) (1 week= during 3rd dialysis sessions) | Evaluation of pain levels (minimum=0 points, maximum: 10 points) of experimental and control groups in the 1st, 2nd and 3rd dialysis sessions
The visual pain scale is minimum 0 and maximum 10 points. 0 means no pain, 10 means severe pain. st dialysis session= Visual analog pain scores during cannulation were evaluated without any application. nd and 3rd dialysis sessions: Ice application to the patient's hoku point was performed by the researcher for 1 min before the AVF cannulation procedure and during cannulation, and visual analog scale pain scores was filled in during cannulation. Kaleidoscope application was performed to the patient for 5 minutes before AVF cannulation procedure and during cannulation. The visual analog scale pain score was filled in during cannulation. Control Group:visual analog scale pain scores will be evaluated before, during and after AVF cannulation without any intervention after the procedure. |
One week= during 3rd dialysis sessions | |
Secondary | The evaluation of Ice Application and kaleidoscope application | Learning patient experiences regarding ice application and kaleidoscope application via Kaleidoscope Application Patient Experience Form, Patient Experience Form for Ice Application.
The answers of the participants to the questions in the evaluation forms (Kaleidoscope Application Patient Experience Form, Patient Experience Form for Ice Application) are presented as a percentage. They were asked to answer the questions asked in the form as "yes, no, partially". |
After 3rd dialysis session (after one week) | |
Secondary | Sociodemographic and disease-related characteristics | Comparison of sociodemographic characteristics (age, gender) with visual pain scale scores of the experimental and control groups.
Comparison of disease-related characteristics [Body mass index:weight and height will be combined to report BMI in kg/m^2 (weight in kilograms, height in meters=kg/m2), duration of dialysis (months), artery and vein needle size (14,15,16,17 gauge), duration of fistula use, region where the fistula is located)] with visual pain scale scores of the experimental and control groups. NOTE:After the data in all dialysis centers were completed (within about three months), the analysis was performed. |
through study completion, an average of 3rd month. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04907240 -
Observational GORE® VIABAHN® Endoprosthesis With PROPATEN Bioactive Surface Global Registry
|
||
Completed |
NCT02376361 -
Hemodialysis Access Surveillance Evaluation Study
|
N/A | |
Completed |
NCT00479180 -
Safety of Vascugel Treatment After Creation of Arteriovenous Access for Hemodialysis Use
|
Phase 1/Phase 2 |